This legislative proposal aims to enhance the drug development process for rare diseases by establishing structured meetings that facilitate collaboration among various stakeholders, including researchers, medical experts, drug developers, and patient organizations. The initiative, led by the Reagan-Udall Foundation, seeks to address scientific challenges and streamline the approval of new treatments for these conditions.